Search Results
Your search for ,ArM matches 4692 pages
Showing 4501 - 4550Nipple-Sparing Mastectomy as Safe as More Radical Procedures for Appropriate Patients
Mastectomies that preserve the nipple and an envelope of breast skin are as safe as more radical breast cancer operations for qualifying patient populations, according to one of the largest meta-analyses of studies involving women treated with this increasingly popular approach. Speaking at the...
FDA Approves Ramucirumab for Metastatic Colorectal Cancer
The U.S. Food and Drug Administration today approved ramucirumab (Cyramza) for use in combination with FOLFIRI (leucovorin, fluorouracil, irinotecan) for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first-line bevacizumab (Avastin)-, oxaliplatin-,...
AACR 2015: Metformin Use May Not Improve Pancreatic Cancer Survival
Metformin use did not improve survival of patients with pancreatic ductal adenocarcinoma in a retrospective cohort study presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract LB-183). “The diabetes drug metformin is being used in some cancer treatment...
AACR 2015: Improved Responses With Ipilimumab-Nivolumab Combination vs Ipilimumab Alone in Advanced Melanoma
Giving the two immunotherapies ipilimumab (Yervoy) and nivolumab (Opdivo) simultaneously yielded better treatment responses than ipilimumab alone in patients with advanced melanoma who received no prior treatment, according to phase II clinical trial data presented at the AACR Annual Meeting 2015,...
AACR 2015: Investigational CART-meso Immunotherapy Feasible for Patients With Advanced Cancers
Patients with advanced cancers who received mesothelin-directed chimeric antigen receptor–modified T cells (CART-meso), a type of investigational adoptive immunotherapy, tolerated the treatment well, and there was evidence that the infused immune cells persisted in the patients’ blood...
AACR 2015: Pembrolizumab Is Better Than Ipilimumab for Advanced Melanoma in Phase III Trial
In the first randomized trial to compare two U.S. Food and Drug Administration–approved immune checkpoint inhibitors as first-line therapy for patients with advanced melanoma, pembrolizumab (Keytruda) yielded significantly better treatment outcomes than ipilimumab (Yervoy) for all endpoints...
Addition of Bevacizumab to Chemotherapy Extends Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer
In a phase III study of women with ovarian cancer, researchers found that the addition of bevacizumab (Avastin) to standard chemotherapy extended median overall survival by 5 months compared to standard chemotherapy alone. The bevacizumab combination was also associated with a significant...
No Improvement in Complete Remission Rate With Cytarabine Plus Amonafide L-Malate vs Daunorubicin in Secondary AML
In a phase III trial reported in the Journal of Clinical Oncology, Stone et al found that the combination of cytarabine and amonafide L-malate, a DNA intercalator and non–ATP-dependent topoisomerase II inhibitor, did not improve complete remission rate compared with cytarabine plus...
Outcomes of Phase II Basket Trial of Molecular Profiling and Targeted Therapy in Advanced Thoracic Malignancies
In a basket trial (CUSTOM) reported in the Journal of Clinical Oncology, Lopez-Chavez et al performed molecular profiling of tumors in patients with advanced non–small cell lung cancer (NSCLC), small cell lung cancer, or thymic malignancies and assigned those in any of five actionable...
Preclinical Study Shows Promise for the Development of Personalized Cellular Therapy for Brain Cancer
Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be safe and effective at controlling tumor growth in mice that were treated with these modified cells, according a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis...
Aurora Kinase A Inhibitor Alisertib Active in Solid Tumors
In a phase II study reported in The Lancet Oncology, Melichar et al found that the oral aurora kinase A inhibitor alisertib was active in solid tumors, particularly breast cancer and small cell lung cancer. Aurora kinases play central roles in mitosis. Inhibition of aurora kinase A, which is...
FDA Approves Nivolumab to Treat Metastatic Squamous Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) today approved the PD-1 inhibitor nivolumab (Opdivo) for the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. Nivolumab is a monoclonal antibody that binds ...
FDA Grants Cobimetinib Priority Review for Use in Combination With Vemurafenib in Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for Genentech’s New Drug Application (NDA) for cobimetinib in combination with vemurafenib (Zelboraf) for the treatment of people with BRAF V600 mutation–positive advanced melanoma. The FDA will make a...
FDA Approves Lenalidomide in Combination With Dexamethasone for Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has expanded the existing indication for lenalidomide (Revlimid) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma. Lenalidomide plus dexamethasone was previously approved in June 2006 for use in multiple myeloma...
Lenvatinib Shows Promise for Patients With Radioiodine-Refractory Thyroid Cancer in Phase III Study
In a phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral antiangiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer. Their findings are published by...
Phase III Study Shows Significant Benefit of Obinutuzumab in Refractory Indolent Non-Hodgkin Lymphoma
In a preplanned interim analysis of the phase III GADOLIN trial, obinutuzumab (Gazyva) plus bendamustine (Trenada) followed by obinutuzumab alone was found to significantly improve progression-free survival compared to bendamustine alone in patients with indolent, refractory non-Hodgkin lymphoma....
Patients With Detectable PSA After Radical Prostatectomy May Benefit From More Aggressive Radiotherapy, 10-Year Post-Treatment Analysis Shows
Prostate cancer patients with detectable prostate-specific antigen (PSA) following radical prostatectomy should receive earlier, more aggressive radiotherapy, according to a study published by Wiegel et al in the International Journal of Radiation Oncology • Biology • Physics. German ARO ...
FDA Approves Palbociclib in Combination With Letrozole for Advanced Breast Cancer
The U.S. Food and Drug Administration has granted accelerated approval to palbociclib (Ibrance) in combination with letrozole for the treatment of postmenopausal women with estrogen receptor–positive, HER2-negative metastatic breast cancer who have not yet received an endocrine-based therapy. ...
Ibrutinib Active in Previously Untreated and Relapsed/Refractory CLL With TP53 Aberrations
In a phase II study reported in The Lancet Oncology, Farooqui et al found that single-agent ibrutinib (Imbruvica) had good activity in patients with previously untreated or relapse/refractory chronic lymphocytic leukemia (CLL) with TP53 aberrations. Study Details In this single-arm trial, 51...
RTOG 9804 Trial Shows Reduced Local Failure With Radiotherapy After Breast-Conserving Surgery in Patients With Good-Risk DCIS
As reported in the Journal of Clinical Oncology by McCormick et al, the Radiation Therapy Oncology Group (RTOG) 9804 trial showed that radiotherapy after breast-conserving surgery reduced local failure vs observation in women with good-risk ductal carcinoma in situ (DCIS). The study was designed...
Expanded Analyses of Phase III MM-398 NAPOLI-1 Study Substantiate Positive Results of MM-398 Combined With Fluorouracil/Leucovorin
Additional analyses from the global phase III NAPOLI-1 study of MM-398 (aka PEP02), a nanoliposomal encapsulation of irinotecan, in metastatic pancreatic cancer were presented by Chen et al in an oral session at the 2015 Gastrointestinal Cancers Symposium (Abstract 234). The primary analysis ...
Adding Ziv-Aflibercept to FOLFIRI Results in Persistent Improvement in Overall Survival in Patients With Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer showed a continued and persistent improvement over time in overall survival when they received ziv-aflibercept (Zaltrap) in addition to FOLFIRI (irinotecan, fluorouracil, leucovorin), reported by Ruff et al in the European Journal of Cancer. Survival was...
Long-Term Follow-up Shows Favorable Overall Survival Rates With Concurrent Neoadjuvant Chemoradiotherapy Regimens in Rectal Cancer
Patients with locally advanced rectal cancer who receive neoadjuvant radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a 4-year overall survival rate of 85% and 75%, respectively, according to a study reported by Wong et al in the International Journal ...
Low-Level Laser Therapy May Reduce Limb Volume and Pain in Patients With Breast Cancer–Related Lymphedema
In a meta-analysis of patients with breast cancer–related lymphedema, low-level laser therapy was associated with reduced limb volume and pain levels, according to a report by Smoot et al in the Journal of Cancer Survivorship. However, the investigators noted that regarding pain management,...
Stereotactic Body Radiation Therapy Plus Chemotherapy Improves Survival Among Patients With Stage IV Lung Cancer
A clinical trial that combined stereotactic body radiation therapy (SBRT) with erlotinib chemotherapy more than doubled survival rates for certain patients with stage IV lung cancer patients, reported Iyengar et al in the Journal of Clinical Oncology. SBRT is a type of radiation therapy in which a ...
Exercise Improves Aromatase Inhibitor–Induced Arthralgia in Breast Cancer Survivors
In the HOPE study reported in the Journal of Clinical Oncology, Irwin et al found that a program of aerobic exercise and strength training produced significant improvement in aromatase inhibitor–associated arthralgia in breast cancer survivors. Study Details In the study, 121 women with...
First-Line Crizotinib Improves Progression-Free Survival vs Chemotherapy in ALK-Positive NSCLC
In a phase III PROFILE 1014 trial reported in The New England Journal of Medicine, Solomon et al found that the ALK inhibitor crizotinib (Xalkori) improved progression-free survival vs standard chemotherapy in first-line treatment of advanced ALK-positive non–small cell lung cancer (NSCLC)....
FDA Approves Lanreotide Injection for Gastroenteropancreatic Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) today approved lanreotide (Somatuline Depot Injection) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. Lanreotide was previously approved for...
SABCS 2014: BOLERO-3: Everolimus Plus Trastuzumab/Paclitaxel Misses the Mark in First-Line HER2 Advanced Breast Cancer
The addition of everolimus to weekly trastuzumab (Herceptin) plus paclitaxel did not improve outcomes in the phase III BOLERO-1/TRIO-019, but did provide a “signal” in the hormone receptor–negative subset. The study was reported at the 2014 San Antonio Breast Cancer Symposium by...
FDA Approves Ramucirumab Combination for Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) today approved ramucirumab (Cyramza) for use in combination with docetaxel for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK...
SABCS 2014: Adding Carboplatin to Neoadjuvant Therapy Increases Pathologic Complete Response Rates Across Subtypes in Triple-Negative Breast Cancer
Among women with triple-negative breast cancer, both basal-like and non–basal-like tumors were equally likely to demonstrate a pathologic complete response to neoadjuvant chemotherapy, but they responded differently to exposure to carboplatin and bevacizumab (Avastin), in an analysis of the...
SABCS 2014: Ovarian Suppression Added to Hormonal Therapy Reduces Risk of Recurrence in Some Premenopausal Women
Results of the large international SOFT trial present a convincing argument for the addition of ovarian function suppression to adjuvant hormonal therapy to reduce the risk of recurrence in premenopausal women with hormone receptor–positive breast cancer at high enough risk to be treated with ...
SABCS 2014: PI3K Inhibition With Pictilisib in Hormone Receptor–Positive Breast Cancer Not Ready for Prime Time
Interest is high in studying the PI3K pathway in hormone receptor–positive breast cancer, but it is not clear which of the PI3K inhibitors under development—if any—will be a “home run.” Adding the pan-class I selective PI3K inhibitor pictilisib to fulvestrant...
FDA Approves Denosumab for the Treatment of Hypercalcemia of Malignancy Refractory to Bisphosphonate Therapy
The U.S. Food and Drug Administration has approved a new indication for denosumab (Xgeva) for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. Denosumab was approved and granted Orphan Drug designation by the FDA, which is reserved for drugs that are intended for...
ASH 2014: Post-Transplant Brentuximab Vedotin Improves Progression-Free Survival in Hodgkin Lymphoma Patients
In Hodgkin lymphoma patients at risk for disease progression following autologous stem cell transplant, early consolidation post-transplant with brentuximab vedotin (Adcetris) significantly improved progression-free survival compared with placebo in the phase III AETHERA trial. The findings were...
ASH 2014: HIV-Related Lymphoma Can Be Safely Treated With Autologous Hematopoietic Cell Transplant
Patients with human immunodeficiency virus (HIV)-related relapsed/refractory lymphoma can safely undergo autologous hematopoietic cell transplant, according to results of a phase II multicenter trial. At many centers, patients with HIV-related lymphoma are currently excluded from this potentially...
ASH 2014: Carfilzomib-Based Triplet Yields ‘Unprecedented’ Duration of Remission in Relapsed Myeloma
The phase III global ASPIRE trial documented an “unprecedented” duration of remission in relapsed multiple myeloma patients receiving carfilzomib (Kyprolis) plus a standard-of-care doublet, according to A. Keith Stewart, MD, of the Mayo Clinic in Scottsdale, Arizona, who presented the...
RSNA Awards Gold Medal to Three Leaders in Radiology
The Radiological Society of North America (RSNA) awarded the Gold Medal, the organization’s highest honor, to three individuals at the RSNA 100th Scientific Assembly and Annual Meeting: Gary J. Becker, MD, of Tucson; Allen S. Lichter, MD, FASCO, of Alexandria, Virginia; and Etta D. Pisano,...
FDA Approves Bevacizumab Plus Chemotherapy for Platinum-Resistant, Recurrent Ovarian Cancer
The U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. AURELIA Trial ...
Comparable Disease Control, Less Morbidity With Axillary Radiotherapy vs Surgery in Breast Cancer Patients With Positive Sentinel Node
In a noninferiority phase III EORTC 10981-22023 AMAROS trial reported in The Lancet Oncology, Donker et al found that axillary radiotherapy provided comparable disease control and was associated with less morbidity compared with axillary surgery in breast cancer patients with a positive sentinel...
FDA Approves Ramucirumab in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The U.S. Food and Drug Administration (FDA) today approved ramucirumab (Cyramza) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Ramucirumab was approved in April 2014 as a single agent for the treatment of...
Neoadjuvant Chemotherapy Plus Two Anti-HER2 Agents Optimal for HER2-Positive Breast Cancer
For women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, combining two anti-HER2 agents with chemotherapy is the most effective treatment modality in the neoadjuvant setting, according to a meta-analysis published in the Journal of the National Cancer Institute. The...
Single-Day Education Program Mitigates Psychosexual Side Effects of Risk-Reducing Salpingo-Oophorectomy
More women are undergoing salpingo-oophorectomy as a cancer prevention measure, but many are unaware of the potential sexual or psychological side effects of the procedure. A new study by researchers at Dana-Farber Cancer Institute demonstrated that a half-day educational program can help ...
Rate of Cancer Detection at Risk-Reducing Salpingo-Oophorectomy
In a study reported in the Journal of Clinical Oncology, Sherman et al found occult cancers in 2.6% of high-risk women undergoing risk-reducing salpingo-oophorectomy. Study Details The study involved 966 asymptomatic high-risk women age ≥ 30 years who underwent risk-reducing...
FDA Approves Bortezomib Injection for Previously Untreated Patients With Mantle Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma. This is the first treatment in the United States to be approved for use in previously untreated patients with mantle cell lymphoma. Bortezomib was...
Updated GEM2005 Trial Confirms Benefit of Melphalan/Bortezomib Combination in Elderly Multiple Myeloma Patients
Melphalan in combination with bortezomib (Velcade) should be maintained as one of the standards of care for the treatment of elderly patients with multiple myeloma, concluded Spanish trialists reporting updated results from the GEM2005 study comparing bortezomib/melphalan/prednisone with...
Enhanced Benefit Shown With FOLFIRI/Ziv-Aflibercept in Subset of Patients With Metastatic Colorectal Cancer
The survival benefit demonstrated in the VELOUR study for FOLFIRI (irinotecan, fluorouracil [5-FU], leucovorin) plus ziv-aflibercept (Zaltrap) vs FOLFIRI plus placebo in metastatic colorectal cancer patients who had disease progression on oxaliplatin-based chemotherapy persisted beyond median...
ESMO 2014: Abiraterone Plus Prednisone Significantly Improves Overall Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A final analysis of the phase III COU-AA-302 trial showed that abiraterone acetate (Zytiga) plus prednisone significantly prolonged overall survival compared to an active control of placebo plus prednisone in men with chemotherapy-naive metastatic castration-resistant prostate cancer. The study,...
ESMO 2014: Everolimus Improves Overall Survival in Patients With Advanced Pancreatic Neuroendocrine Tumors
In a phase III trial, treatment with everolimus (Afinitor) resulted in a median overall survival of over 3 and a half years in patients with well-differentiated and progressive pancreatic neuroendocrine tumors, representing what the study authors called a "clinically important" although not...
ESMO 2014: Nivolumab Shows Signs of Superior Response Rate Compared to Standard Chemotherapy in Advanced Melanoma
The monoclonal antibody nivolumab achieved superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab (Yervoy), according to preliminary data from a phase III trial presented at the ESMO 2014...
